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Abstract

MODIFIED PAMAM DENDRIMERS IN TUNABLE DRUG-DELIVERY SYSTEMS: A
SUSTAINED-RELEASE DENDRIMER HYDROGEL FOR ANTI-GLAUCOMA DRUGS
AND SURFACE-ENGINEERED MACROPHAGES AS NANOPARTICLE CARRIERS FOR
TARGETED ANTI-CANCER THERAPY
By Christopher Alan Holden, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Biomedical Engineering at Virginia Commonwealth University

Virginia Commonwealth University, 2017

Director: Hu Yang, Ph.D., Professor, Chemical and Life Science Engineering
Co-chair: Rebecca Heise, Ph.D., Associate Professor, Biomedical Engineering

Two specific drug-delivery applications were sought in this work using polyamidoamine
(PAMAM) dendrimers. One drug-delivery system used a novel dendrimer hydrogel (DH) for
sustained delivery of anti-glaucoma drugs. In this work, PAMAM G3.0 dendrimers were
covalently bonded with poly(ethylene glycol) (PEG12000) molecules which were subsequently
acrylated, resulting in photocurable DH conjugates. For pharmacological studies, DH were
loaded with a solution of intraocular pressure lowering drugs, brimonidine and timolol maleate,

and were characterized for in vitro release and ex vivo transport and uptake. DH formulations
were shown to increase the loading of drug molecules, increase transcorneal drug delivery, and
exhibit sustained-delivery of drug molecules. A second drug-delivery system, utilizing cellsurface engineering, intended to increase the targeting ability of highly toxic anti-cancer drugs to
curtail systemic effects. In particular, Qdots and 5-(aminoacetamido) fluorescein-labeled
polyamidoamine dendrimer G4.5, both of which were coated with amine-derivatized
polyethylene glycol, were immobilized to the sodium periodate-treated surface of RAW264.7
macrophages through a transient Schiff base linkage. Further, a reducing agent sodium
cyanoborohydride was applied to reduce Schiff bases to stable secondary amine linkages. The
distribution of nanoparticles on the cell surface was observed by fluorescence microscopy and
was found to be dependent on the stability of the linkages tethering nanoparticles to the cell
surface.

Chapter 1 Introduction

Exciting frontiers in pharmaceutical science research arise from limitations in the innate
kinetics of drug molecules. Drug molecules have unique profiles in their distribution, uptake,
absorption, and clearance within the body. These pharmacokinetic properties are typically
dependent on route of administration(ROA) and formulation. Each ROA has different sets of
pros and cons depending on the class of drug molecules and the clinical target. The goal in drug
delivery is to maximize the efficiency of a drug formulation to reach the therapeutic window of
drug molecules within the body. Drug delivery strategies rely not only on the concentration and
frequency of dosing, but also on the vehicle of the drug formulation. Traditional clinical
strategies include, but are not limited to, drugs in solid or liquid form administered
intravenously, orally, nasally, rectally, topically, or subcutaneously. Therapeutic efficacy is
based on the innate pharmacokinetics; yet, by using biomaterial research and cellular therapies
the efficacy of drugs can be enhanced. This project utilizes biomaterial nanoparticle vehicles to
enhance drug molecules and treatment options.
Biomaterial research has led to advances in wound healing, tissue engineering, and drug
delivery. Natural and synthetic classes of biomaterials are used either independently or in
conjunction with other materials and biologics for desired applications. In this work
polyamidoamine (PAMAM) dendrimers, a class of synthetic polymeric nanoparticles, are
explored for their versatile physical and chemical properties. Dendrimers are a highly organized
polymer branching from an ethylene diamine core structure that are stepwise synthesized to
create amine terminated (full generation [X.0]) and carboxyl terminated (half generation [X.5])
1

nanoparticle. The amine and carboxyl functional groups allow for a highly tunable molecule
using organic chemistry conjugations. This work employs PAMAM dendrimers as a key
component in biomaterial drug-delivery systems including a topical hydrogel system for
sustained ocular delivery as well as proof of concept for targeted drug delivery using a cellular
vehicle hybridized with dendrimers.

1.1 Anti-glaucoma drug delivery
Vision, as one of the main sensory inputs, is critical in many aspects of everyday life.
Visual-impairment can have a huge impact on quality of life, healthcare costs, and
socioeconomic outcomes. Some of the major causes of visual-field loss are cataracts, age-related
macular degeneration, diabetic retinopathy, retinal vein-occlusive diseases, and glaucoma.
Specifically, glaucoma affects 2.7 million people in the United States alone(1). Currently there
are no cures for glaucoma, but there are effective drug molecules for treating the causes of
vision-loss in glaucoma patients. The typical treatment for glaucoma are topical eye-drop
solutions administered multiple times daily; however, this tedious regimen often decreases
patient compliance which leads to chronic and progressive neurodegeneration of the optic nerve.
A major goal in anti-glaucoma drug delivery is to decrease the frequency of dosing to increase
patient compliance and outcomes. This project proposes a topical dendrimer hydrogel co-drug
formulation as a sustained delivery approach for treatment.

1.2 Targeted dendrimer delivery with cellular therapy
Many traditional cancer therapies use highly toxic drugs administered at systemic doses.
Drug targeting is desired to decrease the harmful effects of chemotherapeutics on healthy cells.
This project proposes an interdisciplinary approach which utilizes tools from cell biology to
integrate biomaterial engineering with cancer research. Monocytes have an inherent ability to
2

infiltrate tumors based on factors such as hypoxia and chemoattractants. The overall goal is to
utilize monocyte-targeting to deliver cancer therapies. This project sought to demonstrate that
surface modification of monocytes is possible to allow hybridization with a drug-loaded
biomaterial, specifically half-generation PAMAM dendrimer conjugates (PAMAM G4.5). A
molecular approach through cell-surface modification of sialic acid residues on monocytes is
explored. Sodium periodate modifies sialic acid into aldehyde groups which are reactive to the
amines of G4.5-PEG-NH2 conjugates through transient Schiff linkages. A stabilizing reagent,
sodium cyanoborohydride, is used to reduce the linkage to a stable amide bond. In review, this
thesis covers the synthesis and characterization of two drug delivery systems and demonstrates in
vitro and ex vivo testing to substantiate further work using these novel approaches.

3

Chapter 2 Background and Significance

2.1.1 Glaucoma
According to a 2014 World Health Organization fact sheet, 285 million people
worldwide suffer from visual impairment, where up to 80% of incidences are preventable or
curable. Unoperated-upon cataracts and uncorrected refractive errors account for 76% of all
cases of visual-impairment, but with treatment visual-field loss is reversible(2). Glaucoma, on
the other hand, is the number one cause of irreversible blindness in the world(3). With early
treatment, however, optic nerve damage and visual-impairment can be reduced or prevented. It is
estimated that currently 60 million people suffer from glaucoma and by 2040 it is projected 112
million people will have glaucoma(4, 5). There is a clear clinical need to reduce the negative
effects of the disease which include a lower quality of life and higher economic burden for those
experiencing vision-loss.
Glaucoma describes a group of neuropathies which cause a progressive degeneration of
retinal ganglion cells, cupping of the optic disc, and thinning of retinal nerve fibers(6). The two
main classifications of glaucoma are open-angle and angle closure. In open-angle glaucoma,
there is an opening between the iris and cornea, but the aqueous humor outflow is restricted
through the trabecular meshwork. In angle-closure glaucoma, the drain between iris and cornea
is closed and outflow through the trabecular meshwork is blocked. Currently there is no
treatment for reversing nerve damage in glaucoma patients, so treating the main risk factor of
increased intraocular pressure (IOP) is the primary clinical goal. IOP is a dynamic balance of
fluid secreted by the ciliary body into the aqueous humor and drainage of aqueous humor. The
4

main treatment options include topical instillation of eye
drops, which typically target either a decreased production
of aqueous humor or increased aqueous humor outflow.
The main clinical IOP-lowering drug classes are described
below(7).

Figure 2.1 Depiction of aqueous humor outflow
adapted from https://www.aao.org/eyehealth/diseases/glaucoma-causes

2.1.2 IOP-lowering therapies

There are 5 major classes of drugs for lowering IOP in patients; Cholinergic agents,
prostaglandin receptor analogues, β-blockers, α-adrenergic agonists, and carbonic anhydrase
inhibitors. Cholinergic agents act on muscarinic receptors on ciliary muscle to increase outflow
via trabecular meshwork. An example is pilocarpine, which often uses a 4 times daily dosing
strategy with side effects including myopia, miosis of the pupil, and dimming of vision(7).
Prostaglandin F receptor(PTGFR) analogues with a once daily dosing increase aqueous humor
outflow by altering ECM in the ciliary muscle/trabecular meshwork. Side effects of PTGFR
analogues include lengthening of eyelashes, thickening of eyelashes, and darkening of the iris(7).
β-adrenergic receptor blockers have an increased tolerability and increased IOP-lowering
efficacy. β -blocker treatments inhibit β-adrenergic receptors in the ciliary epithelium and help to
decrease aqueous humor formation. Side effects of timolol maleate at higher dosing frequencies
include syncope, arrhythmia, and dyspnea. It is thought that decreases in dosing will likely limit
adverse systemic effects(7).
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α-adrenergic agonists, such as brimonidine, lower IOP through stimulation of α2adrenergic receptors which decreases aqueous humor in flow and increases uveoscleral outflow.
Similar to β -blockers, α-adrenergic agonists only lower IOP during the day(7).
Carbonic anhydrase inhibitors are another IOP-lowering class and they decrease aqueous
humor formation by inhibiting carbonic anhydrase II in the ciliary epithelium. Carbonic
anhydrase inhibitors are typically second line agents and are effective day or night(7).
There are also FDA approved drug combination therapies that aim to simultaneously
decrease aqueous humor inflow and increase outflow. These multi-drug formulations have
multiple mechanisms of action and are more effective than single drugs at lowering IOP. The
main issue of IOP lowering drugs is not necessarily the efficacy of action, but the efficiency of
delivery and dosing regimen required to maintain therapeutic drug levels in patients.
2.1.3 Ocular drug delivery
Treatment of ocular diseases involves optimizing drug bioavailability in ocular tissues for
a therapeutic response, where transcorneal permeation is the primary route of drug transport into
the aqueous humor and conjunctival absorption is considered an alternative route of transport.
Systemic drug delivery is typically not feasible for ocular drugs due to the blood-retinal and
blood-aqueous barriers. The main barriers in topical ophthalmic drug delivery include corneal
epithelial tight junctions, lacrimal clearance, conjunctival absorption, metabolism, and
inadvertent protein binding(8). The shortfalls of eye drop formulations include quick precorneal
clearance and low bioavailability of drug leading to a higher dosing frequency for patients. A
high dosing frequency often leads to lower patient compliance and increased side effects. One
solution to increase drug absorption into ocular tissues is to increase corneal residence time via
electrostatic interactions with negatively charged cell membranes as well as binding with native
6

proteins such as mucin. Creating a more bioadhesive formulation would help alleviate some of
the drug loss due to tearing. The main attachment targets for bioadhesion on the ocular surface
are the mucous coat on the surface tissue and epithelial tissues(9).
Some ocular drug delivery formulations have used water soluble polymers, nanoparticles,
liposomes, cellulose derivatives, mucus glycoproteins, and hyaluronate to increase corneal
residence time through increased viscosity and bioadhesion. Likewise, in situ forming gels
activated by pH or temperature have also been used to enhance transcorneal delivery.
Dendrimers have been tested as ophthalmic vehicles for pilocarpine nitrate; in this work they
were proposed to exhibit bioadhesiveness and increased corneal residence times. Other solutions
aim to transiently increase transcorneal delivery through use of absorption promoters or
penetration enhancers. Examples of penetration enhancers include calcium chelators (such as
EDTA), surfactants, and micelles which disrupt epithelial tight junctions to allow increased
paracellular permeation(9, 10). An ideal ocular formulation will likely combine characteristics
including increased viscosity, increased precorneal residence, increased transcorneal transport,
sustained delivery, and concomitant drugs.
2.1.4 Hydrogels
Physical and chemical hydrogels
Hydrogels are networks of polymers and colloids with either physical or chemical
crosslinking that retain aqueous solutions. Physical hydrogels are networks held together by
polymer entanglements, ionic interactions, or hydrogen bonding. Physical hydrogels can include
anionic and cationic polymer combinations such as alginate and chitosan that self-entangle into
gels. Polymers such as PEG-PLA, agarose, and gelatin can dissolve in water as random
structures and can organize into helices upon heating or cooling processes to form rigid and
7

reversible sol-gels(11, 12). Chemical hydrogels have networks linked with covalent bonds and
are the most frequently explored class in hydrogel research. Chemical hydrogels involve
covalently crosslinking functional side chains or end groups of polymers with monomers or
chemical treatments. UV and ionizing radiation are also used as crosslinking methods through
free radical polymerization. Typically, physical hydrogels are weaker, more transient, and less
customizable than chemical hydrogels(13).
Natural and synthetic hydrogels
Other than physical or chemical crosslinking, hydrogels can also be characterized as
either having synthesized or naturally occurring components. Natural hydrogels are formed from
proteins and polysaccharides including extracellular matrix proteins such as collagen and gelatin
or polysaccharides such as agarose or alginate. Natural hydrogels typically exhibit better
qualities of biocompatibility and biodegradation, but they are often less-customizable. Synthetic
hydrogels include artificial polymers that are synthesized in labs. Artificial hydrogels are highly
tunable and easily tailored to specific applications in the synthesis process. Water content,
mechanical properties, chemical properties, mesh size, and polymer length can all be customized
in synthetic hydrogels for specific biomedical functions(13).
Hydrogels in biomedical applications
Hydrogels show promising characteristics for controlled release of bioactive molecules
and as scaffolds for cell growth. Design considerations for hydrogels include gelation conditions,
biodegradation, biocompatibility, and synthesis. Hydrogels can also respond to biological
conditions such as changes in temperature, pH, and ionic conditions to swell or contract; such
responses by hydrogels allow exploitation of local conditions in delivery systems. Examples of
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commercially available hydrogels include wound dressings, drug delivery vehicles, tissue
scaffolds, contact lenses, diapers, and biosensors(13).
Dendrimer hydrogels
Dendrimer nanoparticles, with their highly branched architecture, are ideal molecules for
crosslinking into hydrogel networks due to their surface functionality. Previous work with
PAMAM dendrimers tested the effects of PEG length and degree of PEGylation, PEG molecules
per dendrimer, in formation of photocurable hydrogels. It was demonstrated that PEG12,000
created effective solid hydrogels after coupling with acrylate groups. Demonstrating synthesis of
dendrimer hydrogels (DH) shows promise in drug delivery and tissue engineering applications.
The hydrogel network is potentially a scaffold for cell growth or as a substrate for loading both
hydrophobic and hydrophilic drug molecules. Recent research demonstrates PEGs with
predetermined breaking points could add further control to PEGylated DHs and lead to new
routes of biodegradation and sustained delivery(14, 15).

2.2 Dendrimers
Dendrimers are a class of nanoparticles with a highly organized structure resembling the
branches or roots of trees. Expanding from a central core molecule, each stepwise monomer
addition branches at a covalent bond to double the existing number of terminal groups. As the
dendrimer expands, there is an incremental increase in molecular weight, diameter, and surface
groups.
Dendrimers are favorable vehicles for drug delivery due to their surface group
functionality, low polydispersity, hydrophobic cores, and globular structure. Full-generation
(polycationic) and half-generation (polyanionic) dendrimers, with their amine and carboxyl
terminal groups, allow for an array of organic chemistry coupling techniques. Polycationic
9

dendrimers have a shorter blood circulation time as electrostatic interactions with negatively
charged cell walls lead to a rapid clearance whereas polyanionic dendrimers can have lower
cytotoxicity and longer circulation time in the body as they are repelled by the negative surface
potentials of cell walls. Individual dendrimers can be engineered for biocompatibility, drug
loading, and targeting to satisfy a variety of biomedical applications. Specifically, PAMAM
dendrimers tethered with poly(ethylene glycol) (PEG) chains have stealth properties, solubility in
a range of solvents, and high biocompatibility as they are not readily recognized by the
reticuloendothelial system. The propensity of dendrimers for drug-loading is an advantage over
other systems as multiple drug molecules can be covalently bonded to surface functional groups
of a single dendrimer for concentrated delivery. In addition to covalent drug loading, the
hydrophobic backbone core of dendrimers can encapsulate hydrophobic drugs into the network
with or without surface group loading. These unique properties allow dendrimer systems to have
dual drug-loading to optimize therapeutic responses. Hybridized dendrimers have been used in
polymeric micelles, hydrogels, and targeted drug-delivery with a wide range of functions. The
biological properties and high modification potential of dendrimers makes them ideal building
blocks for many biomedical applications. PEGylated dendrimers show low toxicity, low
immunogenicity, and increased circulation time in the body and are ideal for targeted drug
delivery(16-20).

2.3 Cellular Delivery of Anticancer Drugs
2.3.1 Tumor vasculature
Angiogenesis and irregular vasculature are attributes of solid tumors. Solid tumors are
also associated with vascular permeability factors and poor lymphatic drainage. The irregular
vasculature and permeability factors result in a leaky vasculature which allows nutrients and
10

oxygen to reach rapidly growing tumors; however, this leaky vasculature also facilitates an
enhanced permeability of macromolecules and lipid particles into interstitial space. Once in the
interstitial space, macromolecules accumulate due to the poor lymphatic drainage. These traits
are known as enhanced permeability and retention (EPR). EPR can be a useful tool in treating
tumors using nanoparticle and polymer conjugated chemotherapeutics(21-23). A limiting factor
in using macromolecules or nanoparticles for drug delivery is the mononuclear phagocyte
system(MPS). In the MPS, mononuclear cells are responsible for phagocytosing foreign particles
to remove them from circulation. The addition of polyethylene glycol (PEG) to drug carriers
creates stealth particles which can evade the MPS. PEGylation is a strategy which helps
nanoparticle carriers to avoid phagocytosis and allows particles to accumulate in tumor tissues
due to the EPR effect(23, 24).
Even if drug molecules accumulate in the extratumoral region due to EPR, there may not
be sufficient distribution within tumors as many solid tumors have densely packed cells with
necrotic centers. Nutrient-poor regions within tumor cores results in the formation of areas of
hypoxia, establishment of chemotactic gradients, and heterogeneous microenvironments.
Chemotherapeutic drugs struggle to diffuse passively into tumor cores, limiting the therapeutic
response which potentially leads to drug resistances(25). Additionally, inefficient delivery
necessitates the use of considerably higher drug concentrations, with resultant increased toxicity
to normal cells, a major limiting factor when determining drug dosage. Thus, it is essential to
develop methodology to deliver targeted-drug payloads into tumors to increase the efficacy and
safety of chemotherapies. In this regard, a cellular-based delivery approach promises
considerable advantages over standard drug formulations for treatment.
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2.3.2 Monocyte migration
Blood monocytes play important repair roles in immune responses and are recruited into
damaged or pathologic tissues in response to hypoxic or chemoattractant gradients(26). It has
been demonstrated that monocytes have an innate ability to migrate to hypoxic areas,
specifically, inside tumor spheroids(27). Once they are distributed into tissues, monocytes
differentiate into macrophages. Basic monocyte and macrophage functions include phagocytosis
of foreign particles, cytokine production, and antigen presentation. Monocytes and macrophages
mediate immune and inflammatory responses and are important for recruitment of more immune
cells into tissues(28). The migratory abilities of monocytes are well-documented and, when
activated in response to gradients as mentioned above, could potentially act as suitable delivery
vehicles for targeted therapeutics(29). Monocyte chemoattractant protein-1 (MCP-1) expression
in tumors is shown to recruit monocyte-derived macrophages; studies demonstrate that an
increase in MCP-1 lead to an increase in intratumoral macrophage invasion(30, 31).
2.3.4 Cellular therapies and metabolic engineering
Some chemotherapeutics, such as doxorubicin (DX), have a short plasma half-life. DX
also has a wide biodistribution leading to cardiotoxicity at higher dosages(32, 33). To minimize
negative effects on healthy tissues in vivo, drugs and nanoparticles have been conjugated with
PEG to improve biocompatibity; PEGylating nanoparticles can increase plasma half-life and
affect biodistribution of drugs(24). Additionally, DX has been shown to distribute poorly in
hypoxic, acidic regions of tumors(34).
The proposed research aims to develop a hybrid vehicle consisting of
monocytes/macrophages to which doxorubicin has been conjugated on the cell surface via
polyamidoamine (PAMAM) dendrimer nanoparticles, to test functionality of both monocytes
12

and drug, and to investigate migration into and delivery of drug payload to tumor spheroids in
vitro.
Pathways in metabolic engineering can be used to facilitate chemical modification of
cells, in order to endow them with specific new or enhanced properties. Sialic acid residues are
present on mammalian cell lines and can be modified by sodium periodate (NaIO4) into aminereactive aldehyde groups. The NaIO4 modification allows aldehydes to couple with amines to
form a transient Schiff-based linkage(35, 36). When the bond is exposed to another species,
sodium cyanoborohydride (Na CBH3), the linkage is reduced to a stabilized secondary amine
bond(37). These surface techniques allow for conjugation of amine terminated and drug-loaded
biomaterials on a cell exterior. The external attachment of drug molecules is helpful to protect
the host cell. The use of tumor-targeting monocytes as delivery vehicles is a promising lead in
drug therapy.
In this study, half generation PAMAM dendrimers with 128 carboxyl surface groups
(G4.5) are used. When combined with another polymer, polyethylene glycol (PEG), these
nanoparticles exhibit increased water solubility and biocompatibility(38). Administering Nhydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
hydrochloride allowed COOH surface conjugation to NH2 groups. PEG diamine are conjugated
to activated PAMAM nanoparticles and leave an active NH2 to bind to cell-surface
aldehydes(39). When the degree of PEG loading is high, hydrophobic drugs can be encased at
the dendrimer core(20). The avenue for immobilizing drug-loaded nanoparticles on modified cell
surfaces is evident and has direct advantage over unbound drug formulations.
The overall hypothesis is that targeted delivery of chemotherapeutic drugs will enhance
therapeutic response and enable the use of lower drug concentrations when applied to patients in
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the future. Thus, the goal of the proposed research is to apply what is current knowledge of
cancer biology, immune function, surface science, and biomaterials to create a novel, cutting
edge drug delivery vehicle for cancer chemotherapeutics. This second project proposes to
immobilize drug-loaded nanoparticles on the surface of monocytes for targeted tumor therapy.
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Chapter 3 Polyamidoamine Dendrimer Hydrogel for Enhanced Delivery of
Anti-glaucoma Drugs

The following chapter is adapted from a manuscript accepted in Nanomedicine: Nanotechnology,
Biology and Medicine, July 2012, Volume 8(5), pages 776-783, DOI:
https://doi.org/10.1016/j.nano.2011.08.018
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3.1. Abstract
Dendrimer hydrogel (DH), made from UV-cured poly(amidoamine) PAMAM dendrimer
G3.0 tethered with three polyethylene glycol (PEG, 12000 Da)-acrylate chains (8.1% w/v) in
pH7.4 phosphate buffered saline (PBS), was studied for delivery of anti-glaucoma drugs—
brimonidine (0.1 % w/v) and timolol maleate (0.5% w/v). DH was found to be mucoadhesive
and cytocompatible with human corneal epithelial cells (HCETs). The solubility of brimonidine
in DH was 77.6% higher than that in plain PBS. Both drugs were slowly released over 56-72
hours by DH in vitro. As compared to eye drop formulations (PBS drug solutions), DH resulted
in substantially higher degrees of intracellular drug uptake by HCETs and cumulative transport
across bovine cornea for both drugs as well as significantly higher adsorption of timolol maleate
in corneal epithelium, stroma, and endothelium. This work demonstrated that DHs can enhance
delivery of anti-glaucoma drugs in multiple aspects and represent a novel platform for ocular
drug delivery.

3.2 Background
There is a high clinical demand for treating ocular diseases and priority is in increasing
the delivery efficiency of therapeutic drugs to the eye. To date, safe and effective treatments of
most ocular diseases rely heavily on topical applications due to ease of use and low-cost
manufacturing. Conventional dosage forms including aqueous solutions, suspensions, and
ointments that are administered topically and dominate the global market of ocular drug delivery,
accounting for nearly 90% of marketed formulations.
To treat chronic eye diseases such as glaucoma, considerable efforts have been placed on
exploring new topical drug carriers and formulations to increase ocular residence time of drugs
and increase drug adsorption. Consequently, enhanced drug delivery helps extend the duration of
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drug activity and reduce dosing frequency for patient compliance improvement. Nonconventional delivery systems and formulations for topical application of anti-glaucoma drugs
are under rapid development. Mucoadhesive polymers such as hyaluronic acid and chitosan are
able to enhance retention time and drug penetration through the corneal barriers due to their
bioadhesiveness(9, 40, 41). In situ-forming hydrogels are liquid upon instillation and form
viscoelastic gels in response to environmental changes such as pH or temperature(42-46). The
application of in situ-forming hydrogel results in prolonged precorneal residence time and
increased ocular bioavailability. In addition, since cationic liposomes can be preferentially
captured at the negatively charged corneal surface, they have been investigated as carriers for
delivery of ocular therapeutics(47). Nanoparticles such as PAMAM dendrimers,
polyguanidilyated dendrimers, and poly(butylcyanoacrylate) nanoparticles have also been shown
to improve ocular drug delivery efficiency(10, 19, 48-51).
Recently, we have developed a polyamidoamine (PAMAM) dendrimer hydrogel (DH)
platform, which is made from UV-cured PAMAM dendrimer tethered with polyethylene glycol
(PEG)-acrylate chains(15). By tuning concentration and its structural parameters such as the
degree of PEGylation, PEG length, and acrylate density on the dendrimer, photoreactive
dendrimer PEG acrylate in aqueous solutions can be partially crosslinked to form viscous
solutions or completely crosslinked to form “no-flow” gel in situ upon exposure to UV light in
the presence of an eosin Y-based photoinitiator(15). PAMAM dendrimers are highly branched
nanoparticles with numerous surface groups and charges(52). Different from gels made from
aliphatic polyester-ether hybrid dendritic-linear polymers reported for corneal laceration
repair(53-55), the DH network allows for simultaneous delivery of both hydrophobic and
hydrophilic drugs as needed. The interior hydrophobic core of the dendrimer can encapsulate
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hydrophobic compounds and increase their water solubility and loading amounts(17, 56). When
crosslinked, the PEG network can accommodate hydrophilic drugs. DH is likely to have
excellent cytocompatibility owing to the PEG component. Furthermore, the cationic charges
conferred by the DH possess unique structural characteristics and desirable properties for drug
delivery. Figure 3.1 shows a representation of a drug-loaded dendrimer hydrogel.

Figure 3.1 Representation of drug-loaded dendrimer hydrogel

For ocular drug delivery, the DH promises to have properties superior to dendrimer or
PEG gel alone, each of which have been separately shown to be efficient as ophthalmic vehicles.
Therefore, the objective of this work is to demonstrate the feasibility of utilizing DH as a topical
formulation for ocular drug delivery. The anti-glaucoma drugs brimonidine and timolol maleate
were used as model drugs. Mucoadhesiveness of the DH was characterized in terms of its
interaction between mucin particles. Cytotoxicity of DH formulations and their ability to
enhance water solubility of hydrophobic brimonidine were studied. Further, in vitro drug release,
cellular uptake, ex vivo transcorneal transport, and ex vivo eye tissue uptake of the two drugs
mediated with DH formulations were examined.
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3.3 Methods and Materials
3.3.1 Synthesis of photoreactive PAMAM G3.0-PEG-acrylate conjugates
Photoreactive PAMAM G3.0-PEG-acrylate conjugates were synthesized at room
temperature following our previously reported procedure with modification(15). According to
Scheme 1, PEG diol (12000 g·mol-1) (1 eq.) dissolved in tetrahydrofuran (THF) was reacted with
acryloyl chloride (1 eq.) first in the presence of triethylamine (TEA) (1 eq.). After overnight
reaction while stirring, the salt was removed by centrifugation. The resultant OH-PEG-acrylate
in the supernatant was further reacted with 4-nitrophenyl chloroformate (NPC) (1 eq.) and TEA
(1 eq.). The reaction proceeded overnight while stirring. Upon the centrifugal removal of the salt,
the resultant NPC-PEG-acrylate was dried through rotary evaporation. NPC-PEG-acrylate was
then coupled to PAMAM dendrimer G3.0 in dimethylformamide. After 24 h reaction, G3.0PEG-acrylate conjugates were precipitated in cold ether, dialyzed against deionized water, and
freeze-dried. The conjugates were characterized with 1H-NMR spectroscopy(15, 38, 56). G3.0
coupled with an average of 3 PEG acrylate chains (MW=~43,000 g mol-1) was obtained and used
to prepare anti-glaucoma drug formulations. FI-IR spectra were obtained from solution cast films
on KBr discs using a Nicolet Magna IR 760 spectrometer.

3.3.2 Preparation of anti-glaucoma drug formulations
To prepare combination drug formulations based on DH, 40.5 mg of G3.0-PEG-acrylate
was first dissolved in 500 µL of pH 7.4 phosphate buffered saline (PBS) to have a final
concentration of 8.1% (w/v) in PBS. Afterwards, 0.5 mg of brimonidine and 2.5 mg of timolol
maleate were added to the G3.0-PEG-acrylate PBS solution and then the solution was vortexed.
Following addition of 25 µL of eosin Y photoinitiator solution (0.1% w/w eosin Y, 40% w/w
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triethanolamine, and 4% w/w 1-vinyl-2 pyrrolidinone), the solution was exposed to longwavelength (365 nm) UV light for 30 min and kept overnight under ambient light prior to use.
No further treatment was conducted. The prepared combination drug formulations
(brimonidine/timolol/DH) contained 0.1% (w/v) brimonidine and 0.5% (w/v) timolol maleate on
the basis of initial loading quantities. Single drug DH formulations (i.e., brimonidine/DH and
timolol/DH) were prepared by adding 0.5 mg of brimonidine or 2.5 mg of timolol maleate to 500
µL of 8.1% w/v G3.0-PEG-acrylate PBS solution, mixing the solution with 25 µL of eosin Y
photoinitiator solution, and exposing the solution to UV light for 30 min. PBS control
formulations (i.e., brimonidine/PBS, timolol/PBS, and brimonidine/timolol/PBS) were prepared
by dispersing 0.5 mg of brimonidine and 2.5 mg of timolol maleate individually or in
combination in 500 µL of PBS.

3.3.3 Mucoadhesion tests
To assess mucoadhesive properties of DH formulations, zeta potential was measured for
quantitative analysis of interaction between mucin particles and DH. To prepare mucin particles,
an appropriate amount of gastric porcine mucin was suspended in pH 7.4 PBS and agitated
overnight to generate a 1% (w/v) mucin solution. The solution was then subjected to microprobe
sonication two times at full power using a Branson Sonifier 450 20kHz model sonication
unit(57). 700 µL of mucin particle solution was added to 100 µL of 8.1% (w/v) DH solution.
Zeta potential of mucin particles before and after mixing with DH solution was determined using
a Malvern ZetaSizer Nano ZS90 (Malvern Instruments Inc, Westborough, MA).
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3.3.4 Cytotoxicity assays
To test cytotoxicity of DH formulations, human corneal epithelial cells (HCET, passage #
40) were plated in a 96-well plate at a seeding density of 5000 cells per well and allowed to grow
for 24 hours in serum-containing medium. The medium was removed and the cells were
incubated in serum free medium (200µL); the DH formulations (30µL each, n=3) were added to
the cells or the cells remained untreated (control) for 24 hours. At the end of 24 hours, the media
containing the DH formulations was removed and 200 μL of fresh serum free medium was added
to each well. 20 μL of 5 mg/ml MTT reagent, dissolved in PBS (pH 7.4), was added to each well
and incubated at 37 °C for 4 hours. The medium was aspirated and the resultant formazan
crystals were dissolved in 200 μL of dimethyl sulfoxide. The absorbance of the developed color
was measured at 540 nm using a microplate reader. An identical set of cells were used for a
protein content assay. Protein content was quantified using the Micro BCA Protein Assay Kit
(Pierce Biotechnology, Rockford, IL), where bovine serum albumin was used as a standard.

3.3.5 Brimonidine solubility studies
To estimate the degree of solubilization of hydrophobic brimonidine (Sigma-Aldrich, St.
Louis, MO) in the DH formulation, an excess amount of brimonidine was added to G3.0-PEGacrylate PBS solution (8.1% w/v) and vortexed. G3.0-PEG-acrylate was the precursor of the DH
and was not treated with UV light to avoid the interfering absorption after formation of a turbid
gel. Following overnight equilibration at room temperature, the solution saturated with
brimonidine was vortexed again and then centrifuged to remove solid drug residue(56). The
supernatant was collected and diluted by a factor of 100 in PBS. Its absorbance value (Y) at 248
nm was recorded on a GENESYS™ 6 UV-Visual spectrophotometer. Thus, drug concentration
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[C] (μg/mL) was determined using the following regression equation: [C]=(Y-0.005)/0.063 (58).
Following the same procedure, the solubility of brimonidine in plain PBS at room temperature
was determined for comparison. Measurements were done in duplicate.

3.3.6 In vitro drug release studies
Drug release studies were performed based on a brimonidine/timolol maleate codrug DH
formulation. Briefly, 100 μL of drug-loaded gel solution or eye drop solution was transferred to
Spectra/Por® 7 (MWCO 2000) dialysis tubing (Spectrum Laboratories, Inc., CA) and suspended
in 1.5 mL of PBS (pH=7.4) containing 0.05% sodium azide in 2 mL microcentrifuge tubes. The
tubes were maintained at 37 ± 2 °C and constantly shaken in a shaker incubator. At predetermined time intervals up to 72 hours, the medium outside the dialysis tube was replaced with
1.5 mL of fresh PBS, which was pre-equilibrated to 37 ± 2°C. The amount of drug released into
the dissolution medium was analyzed with LC-MS/MS.

3.3.7 In vitro drug uptake studies
Human corneal epithelial (HCET) cells (passage#40) were seeded in a 48 well-plate at a
seeding density of 5000 cells per well and allowed to grow for 24 hours in serum-containing
medium. The next day, the cell culture medium was removed and the cells were incubated in
serum-free medium (1mL) and the cells were exposed to 150 µL of brimonidine or timolol
maleate gel formulation (n=4), whereas the cells exposed to brimonidine and timolol maleate eye
drop solutions were used as control. After 1 hour exposure at 37 ºC, the cells were washed twice
with 200 µL of cold neutral pH 7.4 PBS and twice with 200 µL of cold acidic pH 5.0 PBS. Cells
were lysed by adding 200 µL of 1% (w/v) Triton X-100 solution to each well and allowed to
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stand for 30 minutes. The cell lysate was scraped from the plate and a suspension was prepared.
To analyze drug concentration, 100 µL of the cell lysate was diluted to 500 µL using acetonitrile,
vortexed for 10 minutes, and centrifuged to collect supernatants and cell lysates. The contents of
brimonidine and timolol maleate in cell washes, supernatants, and cell lysates were analyzed
with LC-MS/MS.

3.3.8 Ex vivo transcorneal transport studies
Corneas were isolated from freshly excised bovine eyes obtained from a local slaughter
house, and mounted in Ussing chambers. 50 μL of DH formulation/eye drop formulation (n=5)
containing 0.1 % brimonidine (50 μg) and 0.5 % timolol (250 μg) was diluted with assay buffer
(pH 7.4) to 1.5 mL and added to the donor side. The following compounds were used for the
preparation of assay buffer: NaCl (122 mM), NaHCO3 (25mM), MgSO4 (1.2 mM), K2HPO4 (0.4
mM), CaCl2 (1.4 mM), HEPES (10 mM), and glucose (10 mM). At 1, 2, 3, 4, and 6 h, 200 μL of
sample solution was collected on the receiver side and then immediately replaced with 200 μL of
fresh assay buffer. At 6 hours, sample solutions on both sides were collected, and the tissues
were removed from the chambers. Drug contents in the sample solutions were analyzed with LCMS/MS.

3.3.9 Ex vivo drug uptake studies
Freshly excised bovine eyes were rinsed with PBS and incubated in a muffin pan partially
filled with PBS, as per a previously reported method(59). A solution of gel formulation or eye
drop formulation (50 μL) (n=4) was administered to the corneal surface and allowed to drain.
Every 15 minutes, 50 μL of fresh PBS was instilled as an eye drop to simulate tear exposure and
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to maintain corneal moisture. At 1 hour, the bovine eyes were dissected to collect aqueous humor
and corneal tissues including epithelium, stroma, and endothelium. Drug contents in the excised
eye tissues were quantified using LC-MS/MS.

3.3.10 Drug extraction and recovery
A liquid-liquid method for extraction of brimonidine and timolol from bovine ocular
tissues was first validated to determine the percentage extraction recovery of brimonidine and
timolol (Table 3.1). An extraction recovery study was performed at 500 ng/mL of analytes for all
the corneal layers isolated in this study. Briefly, 20 mg of each tissue (epithelium, stroma,
endothelium; n = 5) was weighed in a glass tube. 20 μL of standard analyte solution containing
25 μg/mL of timolol and brimonidine, 10 μL of dorzolamide solution (25 μg/mL) as internal
standard (IS) and 470 μL of 2 % NaOH solution (pH 12.8) was added to the above tube. Since
both analytes as well as IS are highly basic molecules, 2 % NaOH solution was used to keep
them under unionized state. Tissues were homogenized using a hand homogenizer on an ice bath
followed by sonication for 10 minutes. To the tissue homogenates 4 ml of ethyl
acetate/dichloromethane mixture (1:1 v/v) was added. The mixture was vortexed for 15 minutes
and then subjected to centrifugation for 10 minutes to collect the organic layer. The organic layer
was blow-dried with nitrogen at 40 ºC. The residue, after evaporation, was reconstituted with 1
mL of acetonitrile-water (75:25 v/v) and subjected to LC-MS/MS analysis. The percentage
extraction recovery was calculated using the following formula:(analyte concentration detected
in the tissue ×100)/(initial concentration of the analyte used).
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Table 3.1 The percent extraction recovery (%) of brimonidine and timolol maleate at 500 ng/mL from bovine corneal epithelium,
stroma, and endothelium (n=5)

Tissue
Corneal epithelium
Corneal stroma
Corneal endothelium

Brimonidine
123.0 ± 21.7
118.0 ± 41.2
112.0 ± 17.7

Timolol maleate
103.0 ± 17.6
120.0 ± 10.1
114.0 ± 26.0

3.3.11 Drug quantification in ex vivo uptake studies
After validating the percentage extraction recovery of the liquid-liquid extraction method,
drug content in the tissue samples from ex vivo uptake study was estimated. Ocular tissues were
weighed and mixed with 490 µL of 2 % NaOH and 10 µL of 25 μg/mL dorzolamide (internal
standard) in 10 mL glass tubes, followed by the same procedure as mentioned in the extraction
and recovery section. To analyze drug levels in the aqueous humor, 50 μL of aqueous humor (~
48 mg) was diluted 5 times with acetonitrile-water mixture (75:25 v/v) containing dorzolamide
as an internal standard and subjected to LC-MS/MS analysis. A final concentration of the
internal standard was maintained at 250 ng/mL for all processed samples as well as standard
samples used for preparing the calibration curve.

3.3.12 LC-MS/MS analysis
LC-MS/MS was applied to determine the concentrations of brimonidine and timolol
maleate. An API-3000 triple quadrupole mass spectrometry (Applied Biosystems, Foster City,
CA, USA) coupled with a PerkinElmer series-200 liquid chromatography (Perkin Elmer,
Walthm, Massachusetts, USA) system was used. Analytes were separated on Zorbax extended
C18 column ( 2.1 x 50 mm, 5 µm) using 5 mM ammonium formate in water (A) and acetonitrile
(B) as mobile phase. The linear gradient elution at a flow rate of 0.3 ml/min with total run time
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of 6 min was as follows: 60% A (0–1.0min), 10% A (2.0– 4.0 min), and 60% A (4.5-6.0 min).
Brimonidine, timolol and dorzolamide (internal standard) were analyzed in positive ionization
mode with the following multiple-reaction monitoring (MRM) transitions: 292 → 212
(brimonidine); 317 → 261 (timolol); and 325 → 199 (dorzolamide).

3.3.13 Statistical analysis
Data were analyzed with analysis of variance (ANOVA) followed by t-test for pairwise
comparison of subgroups using SigmaPlot 11.0 (Systat Software Inc., San Jose, CA). P values
<0.05 were considered statistically significant.

3.4 Results
3.4.1 Characterization of dendrimer hydrogel (DH) formulations
Intermediate OH-PEG-acrylate and final product G3.0-PEG-acrylate (Scheme 1) were
characterized with FT-IR. As shown in Figure 1, a broad absorption band at 3199-3678 cm-1 was
attributed to O-H stretching of the hydroxyl end group of PEG. A strong absorption band at 2889
cm-1 was attributed to C-H stretching of PEG. The presence of acrylate group of PEG was
confirmed by an absorption band at 1728 cm-1 corresponding to C=C stretching and a band at
1650 cm-1 corresponding to C=O stretching. Because of the remaining primary amine groups on
the dendrimer surface, a broad absorption band at 3125-3166 cm-1 indicates N-H stretching. PEG
was coupled to PAMAM dendrimer via an amide linkage. The C=O stretching band at 1650 cm-1
became stronger due to the formation of amide linkages and indicates the success of the coupling
reaction.
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B

Figure 3.2 Synthesis route (A) and FT-IR spectrum (B) of G3.0-PEG acrylate conjugates.

As a viscous gel solution is preferred to solid gel in ocular drug delivery due to its ease of
handling and application, PAMAM dendrimer G3.0 coupled with an average of 3 PEG-acrylate
chains was used to make viscous gel solutions for preparation of anti-glaucoma drug
formulations. Mucoadhesiveness of DH formulation was demonstrated by zeta potential
measurements. The zeta potential of 1% w/v mucin particles in PBS was -7.13±0.77 mv. The
zeta potential changed to -3.6±1.50mv after mixing with DH solution. This shift towards zero
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was attributed to the aggregation of mucin particles as a result of adsorption of DH on the mucin
particles(57).
The effect of plain DH formulations on cellular response was assessed. According to the
MTT assay (Figure 3.3), the DH formulation including photoinitiator neither caused toxicity to
HCET cells nor induced cell proliferation rate. The protein content in the cells was quantified by
using the Micro BCA protein assay kit. It was shown that the protein content in the cells treated
with the DH formulation was just 9.3% less than in the control.

Figure 3.3 Effects of DH gel formulation on HCET cellular activity in comparison with the control. MTT assay and BCA Protein
Assay Kit(Pierce)

3.4.2 Drug water solubility enhancement
It has been documented that PAMAM dendrimers are able to increase the water solubility
of hydrophobic compounds by encapsulating them inside the hydrophobic core(20). PEGylation
can augment the water solubility enhancement properties of dendrimers presumably due to
stabilizing and shielding effects of the PEG layer(17, 56). As dendrimers have been integrated
into a hydrogel network, one envisioned property of a dendrimer hydrogel is its ability to
encapsulate hydrophobic drug molecules inside the dendritic cores, while simultaneously
allowing the loading of hydrophilic drugs in the PEG network. To test the ability of the
28

dendrimer hydrogel to enhance water solubility of hydrophobic drugs, brimonidine was used in
this work. Unlike the commonly used water-soluble brimonidine tartrate in ophthalmic solutions,
brimonidine has a limited solubility in aqueous solutions. Our studies revealed that the solubility
of brimonidine was 392 μg/mL in plain PBS. In sharp contrast, the solubility of brimonidine
dramatically increased to 696 μg/mL in DH formulation, representing a 77.6% increase.

3.4.3 In vitro drug release studies
DH formulation resulted in extended in vitro release of brimonidine and timolol maleate.
It was observed that drug release was sustained
for nearly 72 hours for brimonidine (Figure 3.4A) and nearly 56 hours for timolol maleate
(Figure 3.4-B). Contrastingly, drug in eye drop
formulations was released quickly. Both
A

brimonidine and timolol maleate were released
completely from eye drop formulations within
90 minutes, indicating the eye drop formulations
did not sustain the drug release. Sustained drug
release from DH formulations was attributed to
the entrapment of drug molecules in the PEG

B
Figure 3.4 In vitro release of brimonidine (A) and timolol
maleate (B) in pH 7.4 PBS at 37C

network and the encapsulation by the
nanodomains inside the dendrimers.
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3.4.4 Enhanced drug uptake
The intracellular uptake of brimonidine and timolol maleate by HCETs was substantially
increased by the DH formulations. According to the analysis of drug content in the cells treated
with the DH and eye drop formulations(Figure 3.5), the eye drop brought about an uptake of
3.81±0.28 % for brimonidine and 49.40±2.60 % for timolol maleate, respectively. With the aid
of DH formulations, brimonidine uptake was 76.17±19.47 % and timolol uptake was
69.10±13.70 %. The uptake of hydrophobic brimonidine mediated with the DH formulation was
19-fold higher than its uptake mediated with the eye drop formulation (P = 0.003). This
dramatically enhanced cellular uptake of brimonidine was attributed to its increased water
solubility and its even dispersion in the gel network.

Figure 3.5 Drug uptake in HCET cells treated with DH and eye drop formulations.

3.4.5 Ex vivo transcorneal transport
Transcorneal transport of anti-glaucoma drugs was also enhanced by the DH.
Brimonidine and timolol maleate crossed the cornea at a significantly higher rate with the
application of the DH formulation. For brimonidine, statistically significant differences (p <
0.05) were observed in its transcorneal transport starting from 3 hours (Figure 3.6-A). For
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timolol maleate, statistically significant differences (p < 0.001) were observed in its transcorneal
transport starting from 2 hours (Figure 3.6-B). At 6 hours, 1.06±0.18 % of brimonidine had
cumulatively transported across the cornea, while 13.54±1.83 % of timolol maleate had

A

B

Figure 3.6 Cumulative transport of brimonidine (A) and timolol maleate (B) mediated with DH and eye drop formulations
across the bovine cornea.

cumulatively transported across the cornea. In contrast, the eye drop formulation only resulted in
cumulative transport of 0.77±0.23 % for brimonidine and 6.03±1.55 % for timolol maleate. The
cumulative transport of timolol maleate was much higher than that of brimonidine at the end of 6
hours, regardless of formulation type. This might be attributed to the differences in drug
physicochemical properties such as LogD, which is the most critical parameter influencing
transcorneal drug transport.

3.4.6 Ex vivo eye uptake
This study was conducted to assess the ex vivo uptake of brimonidine and timolol maleate
in ocular tissues after 1 hour of topical instillation. The levels of brimonidine from the hydrogel
formulation were similar to those from the eye drop solution formulation in corneal epithelium,
stroma, and endothelium (Figure 3.7-A). We observed significantly higher levels of timolol
maleate from the hydrogel formulation as compared to the eye drop solution in corneal
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epithelium, stroma, and endothelium (Figure 3.7-B). Particularly, the timolol maleate levels from
the hydrogel formulation were 4.6-fold higher in epithelium, 2.6-fold higher in stroma, and 0.4fold higher in endothelium. However, significant difference in drug level was not observed in the
aqueous humor between hydrogel formulation and eye drop formulation for both brimonidine
and timolol maleate (Figure 3.7-A and Figure 3.7-B), which may be due to the short contact time

Tissue uptake (%)

Tissue uptake (%)

of the formulation with the eye surface and the short duration of the study (1 hour).

A

B

Figure 3.7 Uptake of brimonidine (A) and timolol maleate (B) in bovine corneal epithelium, stroma, endothelium, and
aqueous humor after 1hr topical instillation of DH and eye drop formulations (N=4).

3.5 Discussion
Recently, we have synthesized photocurable dendrimer derivatives, which are PAMAM
dendrimers tethered with multiple polyethylene glycol (PEG) chains and photoreactive acrylate
groups. Exposing dendrimer-derivatives to UV light triggers crosslinking of the reactive acrylate
groups, leading to the formation of a DH network. DH integrates the characteristics and
properties of both a dendrimer and PEG network. The surface charges conferred by terminal
groups on the dendrimer surface can make the hydrogel polyionic with controllable charge
density. The interior, hydrophobic core of the dendrimer can encapsulate hydrophobic
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compounds, dramatically increasing their water solubility and loading amounts. Concurrently,
the crosslinked PEG network can load hydrophilic drugs.
In our previous approach, PEG chains were conjugated to amine-terminated PAMAM
dendrimer first and then photoreactive acrylates were introduced to the dendrimer by reacting
acryloyl chloride ideally with the hydroxyl end groups of PEG chains(15). Acrylate attached to
PEG would respond to UV light exposure to initiate crosslinking reaction. This approach has
proven to be valid for gel formation. Due to the possible shielding effect of PEG, acrylate groups
on the dendrimer surface should be avoided in order to achieve efficient crosslinking. However,
restricting acrylate groups to the distal end of the conjugated PEG chains was beyond control in
that approach as acryloyl chloride has reactivity towards free amine group on the dendrimer
surface. In this work, we modified this approach by reacting acryloyl chloride with PEG diol
first, to ensure that acrylate was restrictively attached to the end of PEG, and then by coupling
PEG acrylate to the dendrimer. Photoreactive dendrimer derivatives in aqueous solutions are able
to become viscous solutions and/or form “no flow” gels in situ upon light exposure by tuning
their concentration and/or structure parameters including the degree of PEGylation, PEG length,
and the density of acrylate groups on the dendrimer.
DH was investigated as a new platform for anti-glaucoma drug delivery. The DH
formulations displayed good cytocompatibility and could dramatically enhance water solubility
of hydrophobic anti-glaucoma drugs such as brimonidine. Brimonidine and timolol maleate
encapsulated into DH were released in a sustained manner. The intracellular uptake of
brimonidine and timolol maleate by HCETs and their transport across the bovine corneal
endothelium were substantially increased by DH formulations as opposed to eye drop solution
formulations. According to ex vivo bovine eye studies, significantly higher levels of timolol
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maleate in corneal epithelium, stroma and endothelium resulted from the application of the gel
formulation. PAMAM dendrimer is known to transiently open tight junctions in the intestinal
epithelium(60). Thus, one possible explanation for the higher uptake in the DH formulations is
the temporary disruption of the tight junctions in the corneal epithelial cell layer. The in vitro and
ex vivo studies indicate that dendrimer hydrogel formulations are capable of enhancing delivery
of anti-glaucoma drugs and represent a novel platform to deliver drugs for the treatment of
ocular diseases such as glaucoma. As a consequence, reduced dosing frequency and sustained
efficacy of ocular drugs are expected and will be studied in future work.
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Chapter 4 Surface Engineering of Macrophages with Nanoparticles to
Generate a Cell-Nanoparticle Hybrid Vehicle for Drug Delivery

The following chapter is adapted from a manuscript accepted in the International Journal of
Nanomedicine: Published 22 December 2009, Volume 2010(5), Pages 25-36, DOI:
https://doi.org/10.2147/IJN.S8339
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4.1 Abstract
Tumors frequently contain hypoxic regions that result from a shortage of oxygen due to
poorly organized tumor vasculature. Cancer cells in these areas are resistant to radiation- and
chemo-therapy, limiting the treatment efficacy. Macrophages have inherent hypoxia-targeting
ability and hold great advantages for targeted delivery of anticancer therapeutics to cancer cells in
hypoxic areas. However, most anticancer drugs cannot be directly loaded into macrophages
because of their toxicity. In this work, we designed a novel drug delivery vehicle by hybridizing
macrophages with nanoparticles through cell surface modification. Nanoparticles immobilized on
the cell surface provide numerous new sites for anticancer drug loading, hence potentially
minimizing the toxic effect of anticancer drugs on the viability and hypoxia-targeting ability of the
macrophage vehicles. In particular, quantum dots and 5-(aminoacetamido) fluorescein-labeled
polyamidoamine dendrimer G4.5, both of which were coated with amine-derivatized polyethylene
glycol, were immobilized to the sodium periodate-treated surface of RAW264.7 macrophages
through a transient Schiff base linkage. Further, a reducing agent sodium cyanoborohydride was
applied to reduce Schiff bases to stable secondary amine linkages. The distribution of nanoparticles
on the cell surface was confirmed by fluorescence imaging, and it was found to be dependent on
the stability of the linkages connecting nanoparticles to the cell surface.

4.2 Introduction
The cell membrane, a semipermeable lipid bilayer, defines the cell boundary and consists
of lipids, proteins and carbohydrates that are responsible for selective uptake of molecules, cellcell interactions, cell-matrix interactions, and many other vital cell activities. Because of the
importance of cell surface interactions to cell and tissue function, various cell surface engineering
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approaches have been explored to modify the cell surface to manipulate cell behavior and
function(61, 62).
Considerable progress has been made in introducing non-native chemical species to the
cell membrane permitting a wide range of applications in biology, medicine, drug delivery, and
tissue engineering(36). A molecule of interest can be attached to the cell surface through a fatty
tether including GPI-anchored proteins(63) and cholesterol-tethered compounds(64). A viable
alternative is to apply enzyme-catalyzed chemical reactions to modify carbohydrates on the cell
surface. For example, existing surface glycoforms can be utilized as acceptors for reactions with
an exogenously applied glycosyltransferase and appropriate activated sugar donor(61, 65). Sialic
acids are the most common terminal sugar residue on the cell surfaces and play an important role
in cell adhesion and recognition. Unnatural sialic acid precursors can be incorporated into cell
surface glycoforms by metabolic engineering(66). Direct covalent reactions can also be applied to
enable chemical modification of cell surfaces(67, 68). One possible approach is to couple
biomolecules of interest to the cell surface via reactive cell surface groups such as aldehydes and
ketones(35, 69). The generation of these reactive cell surface groups may be achieved by direct
chemical or enzymatic treatment, or by the metabolic incorporation of an unnatural molecule that
contains the chosen chemical species.
Cell surface engineering has generated tremendous advantages for drug delivery and tissue
engineering. For example, a synthetic adenovirus receptor inserted to the cell surface via a
metabolic engineering approach facilitates the entrance of adenovirus into cells that are normally
resistant to infection by this virus(70). Uptake of exogenous proteins could be enhanced by
inserting appropriate synthetic receptors(71). Selectively killing tumor cells could be realized by
controlling the targeting of an antibody through tagging tumor cells with a non-natural sugar into
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the polysialic acid molecules on the cell surface(72). Cell surface modification approaches have
also been applied to generate three-dimensional cell aggregates or tissue-engineered constructs
through cell crosslinking(73). A recent study reported that polyethylene glycol (PEG) can be
attached to the surface of islets to circumvent immune rejection during transplantation of
pancreatic islets from donor to a patient(68).
In this work, we designed a novel hypoxia-targeted drug delivery vehicle by hybridizing
macrophages with nanoparticles through cell surface modification. Tumors frequently contain
hypoxic regions that result from a shortage of oxygen due to poorly organized tumor vasculature.
Cancer cells in these areas are resistant to radiation- and chemo-therapy, limiting the treatment
efficacy(29). Macrophages and monocytes have inherent hypoxia-targeting ability and hold great
advantages for selective delivery of anticancer therapeutics to cancer cells in hypoxic areas(27, 29,
74, 75). However, most anticancer drugs cannot be directly loaded into macrophages or monocytes
because of their toxicity. Hybridizing a macrophage cellular vehicle with a synthetic carrier,
particularly nanoparticles, may represent a novel approach for effective delivery of anticancer
drugs to hypoxic regions in solid tumors. Immobilizing nanoparticles on the cell surface provide
numerous new sites for anticancer drug loading, hence potentially minimizing the toxic effect of
anticancer drugs on the viability and hypoxia-targeting ability of the macrophage or monocyte
vehicles.
The focus of the current work was to demonstrate the feasibility of immobilizing
nanoparticles including polyamidoamine (PAMAM) dendrimers and quantum dots (Qdots) to the
macrophage surface through cell surface chemical modification. Dendrimers are highly branched
macromolecules with low polydispersity and well-defined surface functionality. Utility of
dendrimers in this work allowed us to take advantage of their versatility to explore optimal
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approaches for cell-nanoparticle hybridization and realize a high drug payload and assembly of
multiple functional entities necessary for hybridization and drug delivery. Commercially
available quantum dots coated with amine-derivatized PEG was also studied for cell-nanoparticle
hybridization. Qdots have been explored for fluorescence imaging of living cells(76). Although
the limited number of surface groups of Qdots is not advantageous for drug loading, hybridizing
cells with Qdots possessing long-term photostability offers a noninvasive way for cell tracking in
vivo and would provide further evidence to demonstrate the feasibility of the cell nanoparticle
hybridization approach explored in this work.

4.3 Experimental
4.3.1 Materials
Qdot® 525 ITK™ amino (PEG) quantum dots(QD525) and 5-(aminoacetamido)
fluorescein (AAF) were purchased from Invitrogen (Carlsbad, CA). PAMAM G4.5 dendrimer was
purchased from Dendritech (Midland, MI). PEG diamine (MW= ~ 3350 g mol-1), Nhydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC), sodium phosphate buffer (10×), sodium periodate (NaIO4), and sodium cyanoborohydride
(NaCNBH3) were purchased from Sigma-Aldrich (St. Louis, MO). 4’,6-diamidino-2-phenylindole
(DAPI), Dulbecco’s modified Eagle medium (DMEM), sodium hydroxide, paraformaldehyde,
phosphate-buffered saline (PBS), fetal bovine serum (FBS), penicillin, and Trypan blue were
purchased from Fisher Scientific (Pittsburgh, PA).
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4.3.2 Preparation of AAF-labeled PEGylated G4.5 dendrimers (AAF-G4.5-PEG)
Synthesis
The synthesis of G4.5-PEG followed our previous work[21].19 Upon removal of methanol
from G4.5 PAMAM stock solution by rotary evaporation, G4.5 PAMAM dendrimer (5 mg) was
dissolved in 2 mL of sodium PBS (0.1 M, pH=5.5). To this solution were added 5.4 mg of EDC
and 3.2 mg of NHS. After a 15 minute reaction at room temperature, 68.5 mg of PEG diamine
(MW= ~ 3350 g mol-1) predissolved in the buffer solution was added to the reaction solution
dropwise. Then 1.4 mg of AAF predissolved in the buffer was slowly added to the reaction
solution. The reaction mixture solution was stirred in the dark overnight. The resultant AAF-G4.5PEG nanoparticles were purified by dialysis and then freeze dried.

Proton nuclear magnetic resonance (1H NMR) spectroscopy
The 1H NMR spectra of dendrimer derivatives were recorded on a Varian Mercury-300
MHz NMR spectrometer (Varian, Palo Alto, CA). The solvent used was deuterium water (D2O),
which has a chemical shift of 4.8 ppm.

Fluorescence spectroscopy
Fluorescence emission spectra of AAF and AAF-G4.5-PEG in water were recorded on a
Varian Cary Eclipse fluorescence spectrophotometer with an excitation wavelength of 488 nm.
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4.3.3 Preparation of macrophage-nanoparticle hybrid vehicles
As illustrated in Figure 4.1, nanoparticles (Qdots or AAF-G4.5-PEG) were coupled to the
surface of macrophages via either a transient Schiff base linkage or a stable secondary amine
linkage.
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Figure 4.1 Hybridization of nanoparticles and macrophage through cell surface modification. Sialic acid residues on the cell surface
are modified with sodium periodate to generate aldehydes. Aldehydes react with amine group of PEG conjugated to the
nanoparticle surface to form Schiff bases. Schiff bases can be further reduced to stable secondary amine linkages using sodium
cyanoborhydride.

Macrophage-nanoparticle hybrids with a transient linkage (macrophage-T-nanoparticle
hybrids)
RAW264.7 macrophages were plated on coverslips at a density of 1.2×104 cells/well. At
70% confluence, the cells were treated with 0.1 mM cold NaIO4 in 100 µL PBS(pH 7.4), incubated
with shaking for 15 minutes at 4 °C in the dark, and then rinsed with cold PBS three times to
remove NaIO4.(73). Following the NaIO4 treatment, the cells were incubated with 12 µg of
nanoparticles dissolved in 100 µL of PBS for 0-24 hours. The resultant macrophage-Tnanoparticle hybrids were washed with PBS and incubated in PBS. At predetermined time points,
macrophage-T-nanoparticle hybrids were fixed with 300 µL 4% paraformaldehyde for
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fluorescence or confocal imaging. Untreated macrophages incubated with nanoparticles were used
as a control.

Macrophage-nanoparticle hybrids with a stable linkage (macrophage-S-nanoparticle hybrids)
Macrophage-T-nanoparticle hybrids were further treated with 100 µL 0.1 mM NaCNBH3
for 1~2 hours to convert the transient Schiff base linkages to stable amide linkages, washed with
PBS, and incubated in PBS. At predetermined time points, macrophage-T-nanoparticle hybrids
were fixed with 4% paraformaldehyde for imaging. Untreated macrophages incubated with
nanoparticles were used as a control.

4.3.4 pH-dependent cell viability assay
Since RAW264.7 macrophages were subjected to surface modification and the rate of the
stabilizing amide reaction is pH-depdendent, the effect of pH of modifying solutions on their
viability was studied. In brief, RAW264.7 macrophages were initially incubated for two hours in
media of different pH values including DMEM (pH 7.4, control) and PBS (pH 8, pH 9 and pH 10,
adjusted with sodium hydroxide), washed with PBS (pH 7.4) three times, and grown in DMEM
supplemented with 10% FBS and 5% penicillin for 48 hours. Viable cells were counted by using
the Trypan blue assay. In addition, toxicity of 0.1mM NaCNBH3 in DMEM at pH 7.4 was also
evaluated. Cell viability (%)= total number of viable cells in each group/total number of viable
cells in the control × 100.
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4.3.5 Fluorescence image analysis
True-color fluorescence images of the macrophage-nanoparticle hybrids were taken under
a Zeiss Axiovert 200 inverted fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany)
or with a Leica TCS-SP2 AOBS confocal laser scanning microscope(Leica, Solms, Germany).
DAPI nuclear stain was applied for colocalization of nanoparticles. Images were analyzed with
ImageJ software (National Institutes of Health, Bethesda, MD).

4.4 Results and Discussion
4.4.1 Preparation of macrophage-nanoparticle hybrids
In this study commercial QD525 quantum dots coated with an amine-derivatized PEG layer
and synthesized PEGylated carboxyl-terminated PAMAM dendrimer G4.5 were employed for
hybridization with macrophages. PEGylated G4.5 PAMAM dendrimer was labeled with AAF to
allow confirmation of immobilization of nanoparticles on the cell surface by fluorescence imaging.
Polyanionic G4.5 PAMAM dendrimer has a relatively high number of surface groups, negligible
toxicity and immunogenicity, and favorable biodistribution(77). The negatively charged
dendrimers have demonstrated negligible cellular uptake due to their low non-specific interaction
with the negatively charged cell surface. Inclusion of PEG provides dendrimers with favorable
pharmacokinetic and tissue distribution and reduces potential accumulated toxicity and
immunogenicity of the nanoparticles. Importantly, PEG helps nanoparticles to escape from
phagocytosis of macrophages. This is a critical step for constructing the proposed hybrid delivery
system. PEGylated dendrimers of larger molecular weight and with more branches tend to have a
lower accumulation in cells as demonstrated previously(78).

43

Similarly to the QD525 employed in this study, PEGylated G4.5 was designed to have
amine-derivatized PEG chains on the surface, based on which cell surface modification chemistry
was explored. PEGylated dendrimers have been well characterized previously(38, 39, 56, 79, 80).
According to the 1H-NMR measurement, an average of eight PEG chains were coupled to G4.5.
PEGylated G4.5 was labeled with a moderately water-soluble fluorescence probe, AAF. As shown
in Figure 4.2, AAF coupled to the dendrimer has an emission wavelength of 515 nm, which is
identical to the emission wavelength of AAF. The unaltered emission wavelength of AAF
following this coupling strategy was also found in a previous report(81). Furthermore, the
fluorescence emission intensity of AAF coupled to PEGylated G4.5 is significantly higher than
that of AAF prepared in water at saturation, suggesting that AAF coupled to PEGylated G4.5 has
higher water solubility than its unmodified form. The increase in the water solubility of AAF was
attributed to the successful conjugation of AAF to the PEGylated dendrimer.
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Figure 4.2 Fluorescence emission spectra of AAF and AAF-G4.5-PEG.

44

600

620

640

A number of methods have been developed to enable the chemical modification of cell
surfaces. In this project, we employed a simple and well-documented methodology to immobilize
nanoparticles to the macrophage cell surface. In particular, sialic acid residues embedded on the
cell surface were converted to aldehydes with sodium periodate. Our results showed that the
toxicity of NaIO4 was negligible at the concentration of 0.1 mM. This was supported by the work
of Ong and coworkers(73). Aldehydes reacted with primary amine end groups of PEG on the
nanoparticle surface to form Schiff bases. Schiff base linkage is labile and can be cleaved in
aqueous solution by hydrolysis. Accordingly, the macrophage-T-nanoparticle hybrids constructed
are expected to readily release nanoparticles through the cleavage of the transient Schiff base
linkages. We also applied a reducing agent, sodium cyanoborohydride, to reduce Schiff bases to
stable secondary amine linkages(37). It has been reported that sodium cyanoborohydride has high
specificity toward the Schiff base. According to our cell viability studies (Figure 4.3), sodium
cyanoborohydride at 0.1 mM was nontoxic to RAW264.7 macrophages. As the reaction proceeds
more efficiently at basic pH(82). the viability of RAW264.7 macrophages at high pH (8-10) was
evaluated to determine whether the immobilization chemistry can be performed at high pH. As
shown in Figure 4.3, pH affects the cell viability. The viability of RAW264.7 macrophages
remains intact at pH 8 or pH 7.4 with sodium cyanoborohydride. The cell viability dropped slightly
to 88% at pH 9. By contrast, the viability was reduced drastically to 52% at pH 10. The results
suggest that mild basic pH has a minimal impact on the viability of RAW264.7 macrophages and
the optimum pH within that range can be explored for increasing the immobilization efficiency.
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Figure 4.3 pH-dependent viability of RAW264.7 macrophages. Cells were incubated for two hours at the indicated pH and then
assessed by the Trypan blue assay 48 hours later. Nontoxicity of 0.1mM sodium cyanoborohydride in DMEM at pH 7.4 was
confirmed. Note: Bar = SD. Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium.

4.4.2 Fluorescence image analysis of macrophage-Qdot hybrids
Fluorescence microcopy and confocal microscopy were applied to confirm the
hybridization of nanoparticles with macrophages. As shown in Figure 4.4, both macrophage-Tnanoparticle hybrids and macrophage-S-nanoparticle hybrids prepared with QD525 exhibit strong
fluorescence intensity at the edge of the cells, clearly outlining the cell surface. Qualitatively, more
QD525 were taken up in macrophage-T-nanoparticle hybrids as opposed to macrophage-Snanoparticle hybrids, reflecting the stability of the linkage between the nanoparticles and the cell.
Confocal microscopy images in z-sections were taken to further examine the distribution of QD525
over the course of time. Without cell surface modification, QD525 were phagocytosed quickly and
evenly distributed in the cytoplasm (Figure 4.5-A 4h and 14h). Although QD525 were still
internalized, a significant amount of QD525 accumulated at the edge of the cells treated with
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sodium periodate (Figure 4.5-B) or a
combination of sodium periodate and
sodium cyanoborohydride (Figure
4.5-C). QD525 immobilized on the
cell

surface

through

a

stable

secondary amine bond displayed
good stability overnight (Figure 4.5-

10 µm

A

C-14h). In contrast, QD525 linked to
the cell surface via Schiff base
linkages were found to be redistributed in the cell overnight
(Figure 4.5-B-14h).

B
10 µm

Figure 4.4 Fluorescence microscopy images of macrophage-Qdot hybrids. A)
Macrophage-T-Qdot. B) Macrophage-S-Qdot. Original magnification 400x,
scale bar 10 µm.
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20 µm
Figure 4.5 Confocal microscopy images (630×) of macrophage-Qdot hybrids at 4 hours (left panel) or 14 hours (right panel) post
treatment. A) Qdots incubated with untreated macrophages (control); B) Macrophage-T-Qdot hybrids;(C) Macrophage-S-Qdot
hybrids.
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4.4.3 Fluorescence image analysis of macrophage-dendrimer hybrids
Macrophages hybridized with AAF-labeled PEGylated PAMAM dendrimer G4.5 were
also studied. As shown in Figure 4.6-A, the level of the internalization of AAF-G4.5-PEG by
untreated macrophages is low. This confirmed that cationic surface charges and PEGylation indeed
helped to reduce nonspecific internalization by macrophages. Further, an apparently biased
distribution of AAF-G4.5-PEG nanoparticles was observed on the cell surface of macrophages
that were treated with sodium periodate (Figure 4.6-B) or the combination of sodium periodate
and sodium cyanoborohydride (Figure 4.6-C). A significant increase in fluorescence intensity of
macrophage-T-dendrimer hybrids and macrophage-S-dendrimer hybrids as compared to the
control suggests that more dendrimer nanoparticles have been immobilized to the cell surface
and/or internalized by the cells. The amine linkages connecting dendrimers to the cell enabled
macrophage-S-dendrimer hybrids to carry dendrimers stably on the surface for an extended period
of time. We also observed that when the surface-treated RAW264.7 macrophages were incubated
with the same amount of AAF-G4.5-PEG (12 µg), a condition of a high concentration (12 µg/100
µL) and a short incubation (1 minute) and that of a low concentration (12 µg /1.5 mL) and a long
incubation (10 minutes) resulted in a similar hybridization efficiency as determined by confocal
microscopy measurements. Cell viability remained good during the surface treatment.
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Figure 4.6 Confocal microscopy images (630×) of macrophage-dendrimer hybrids. (A) Untreated macrophages
incubated with AAF-G4.5-PEG for 10 minutes and fixed immediately(control); (B) Macrophage-T-dendrimer
hybrids fixed immediately following 10 minute incubation with AAF-G4.5-PEG; (C) Macrophage-S-dendrimer
hybrids fixed at 14 hours following treatment of sodium cyanoborohydride.

To further evaluate the intracellular localization of nanoparticles, we performed a
colocalization assay on AAF-G4.5-PEG with nuclear DAPI staining. Clearly shown in Figure 4.7A, a significant amount of AAF-G4.5-PEG nanoparticles were internalized within one-minute
incubation and accumulated evenly in the cytoplasma with no selectivity towards the cell surface
after overnight culture. Entry of the nanoparticles into nuclei was also observed in the
macrophages. This became more evident when the cells were incubated with AAF-G4.5-PEG for
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an extended period of time (overnight incubation, Figure 4.7-B). In addition, more nanoparticles
were internalized by the cells following the overnight incubation as indicated by the increase in
the fluorescence intensity. Macrophage-S-dendrimer hybrids (Figure 4.7-D) show a stronger
fluorescence intensity at the cell surface and less in nuclei as compared to macrophage-Tdendrimer hybrids (Figure 4.7-C), confirming that the stability of immobilized dendrimers in
macrophage-S-dendrimer hybrids was higher than macrophage-T-dendrimer hybrids.
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Figure 4.7 Colocalization assay of AAF-G4.5-PEG (green) with nuclei (blue) by confocal microscopy (630×). (A) Control 1:
untreated macrophages incubated with AAF-G4.5-PEG for 1 minute, cultured overnight (24 hours), then fixed and
counterstained with DAPI; (B) Control 2: untreated macrophages incubated with AAF-G4.5-PEG overnight (24 hours), then fixed
and counterstained with DAPI; (C) Macrophage-T-dendrimer hybrids: sodium periodate-treated macrophages incubated with
AAF-G4.5-PEG for 1 minute, cultured overnight (24 hours), then fixed and counterstained with DAPI; (D) Macrophage-Sdendrimer hybrids: sodium periodate-treated macrophages incubated with AAF-G4.5-PEG for 1 minute, treated with sodium
cyanoborohydride, cultured overnight (24 hours), then fixed and counterstained with DAPI.

It is apparent that fluorescently labeled nanoparticles were taken into the macrophages
after each treatment. Qualitatively, there is a uniform distribution of fluorescence throughout the
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untreated control groups, suggesting cellular uptake pathways are responsible for this
occurrence. Following surface modification, a pronounced ring of fluorescence is observed
towards the cell surface. Quantitative analysis of the distribution of nanoparticle fluorescence
was attempted with the intensity profiled generated by ImageJ software (Figure 4.8). Since all
confocal images were taken under identical image acquisition settings, the fluorescence intensity
profiles-generated allowed us to quantitatively analyze fluorescence distribution in individual
cells based on their relative fluorescence intensity. For each group, three representative cells
were chosen and analyzed. Individual cells were measured three times from different orientations
with each orientation approximately bisecting midlines. From each profile, intensity values were
recorded from fluorescence peaks at the two cell boundaries and from a fluorescence peak near
the midline of each trace. The results are summarized in Table 4.1. The results from the intensity
traces show that for a nanoparticle incubation of 1 minute there is a 20.8% more fluorescence at
the cell boundaries versus the cell center. For an overnight nanoparticle incubation, there was an
even distribution of fluorescent intensity where the cell walls exhibited a fluorescence value that
was 99.8% of the fluorescence of the midpoint of the slice. Surface modification drastically
increased the ratio of fluorescence between the cell walls versus the cell interior. The
macrophage-T-nanoparticle hybrids showed an 85.2% increase in fluorescence near the cell
exterior, whereas the macrophage-S-nanoparticle hybrids showed a 94.4% increase in cell wall
fluorescence. Based on these measurements we show that there is markedly more fluorescence
near the cell surface for surface-treated groups, whereas there is an even distribution of
nanoparticles in the control groups.
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A
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Figure 4.8 Quantitative analysis of the distribution of fluorescence intensity in representative cells. (A) Control 1; (B) Control 2;
(C) Macrophage-T-dendrimer hybrid; (D) Macrophage-S-dendrimer hybrid. The treatment conditions are detailed in Figure 4.7
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Table 4.1 Summary of the distribution of AAF fluorescence intensity in macrophages subjected to various treatments as
indicated below.

Group
A
B
C
D

[L]
70.3±12.5
58.4±10.6
64.3±10.2
67.5±8.1

[I]
55.0±3.7
57.8±13.5
33.4±8.7
33.6±5.2

[R]
62.6±7.3
57.0±6.4
59.3±12.5
63.2±6.1

([L]+[R])/[I] (%)
120.8
99.8
185.2
194.4

(A) Control 1; (B) Control 2; (C) Macrophage-T-dendrimer hybrid; (D) Macrophage-S-dendrimer hybrid
(The treatment conditions are detailed in Figure 4.7). [L], average fluorescence intensity at the
left cell wall; [I] average fluorescence intensity at the interior of the cell; [R], average
fluorescence intensity at the right cell wall. The original images (n=3) were analyzed with
ImageJ.

4.5 Future work
From a chemistry perspective, this work demonstrated the proof-of-principle of chemically
hybridizing nanoparticles with macrophages through cell surface modification. The reaction
conditions explored in this study were mild to the cells. It should be noted that internalization of
nanoparticles by macrophages seems to be an inevitable process because of their innate phagocytic
capability. Nonetheless, our studies disclosed that cell surface modification provides a means to
retard the internalization progress and alter the intracellular distribution of nanoparticles. A
comprehensive understanding of the trafficking and dynamic distribution of nanoparticles is
needed in order for us to optimize the hybridization process. Reducing nonspecific phagocytic
internalization of nanoparticles will be pursued in our laboratory. The sizes of the QD525 and
PAMAM dendrimers as an important factor affecting nanoparticle internalization by cells will be
studies. PAMAM dendrimers have a versatile structure ideal for construction of drug delivery
systems and have been extensively studied by many groups, including us(17, 18, 83, 84). Future
work will include hybridization of drug-carrying dendrimers and/or QD525 with macrophages and
studying the delivery efficiency of such a new drug vehicle in terms of drug distribution in hypoxic
areas using in vitro spheroid models and animal models.
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4.6 Conclusions
QD525 and dendrimers were immobilized to the macrophage cell surface either through a
transient Schiff base linkage or a stable amine linkage. The distribution of nanoparticles on the
cell surface was confirmed by fluorescence imaging and was found to be dependent on the stability
of the linkages connecting nanoparticles to the cell surface. Achieving homogeneous distribution
of anticancer drugs within tumors remains one of the major challenges in cancer chemotherapy
and is critical for treatment effectiveness. The current study has explored an innovative way of
utilizing nanoparticles and cellular vehicles for anticancer drug delivery. Development of a cellnanoparticle hybrid vehicle through cell surface modification would utilize the best aspects of both
cellular carriers and nanoparticles and may help to improve anticancer drug distribution and
penetration in tumors.
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Chapter 5 Summary and Continuing Work

This work explored the use of PAMAM dendrimers in two drug-delivery systems. These
preliminary studies have provided promising results for continuing the work on dendrimers in
hydrogels and in cell-surface engineering.

5.1 DH formulations
DH formulations were shown to increase the loading of drug molecules, increase
transcorneal drug delivery, and exhibit sustained-delivery of drug molecules. These DHs show
potential to reduce dosing frequency through sustained-delivery and increase drug bioavailability
through increased precorneal residence and transcorneal transport. The in vitro and ex vivo
studies explored in this work set the stage for continued experiments in vivo.
Based on the work in this thesis, IOP-lowering ability and sustained-delivery of
concomitant DH was studied in rabbits. Continued work combined poly(lactic-co-glycolic acid)
(PLGA) nanoparticles in DH formulations; this work found sustained drug levels of brimonidine
and timolol maleate for one week following a single dose in rabbit ocular tissues. This PLGADH system also led to a sustained IOP reduction of 18% or higher for 4 days. This platform
shows continuing promise for treating chronic eye diseases, including glaucoma(85).
This project has evolved from the use of a photoinitiator and UV-curing system based on
concerns of potential hazards and stability issues of the DH formulations. The Eosin-Y
photoinitiator and UV system works on the mechanism of creating free radicals for crosslinking
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within the PEG network and free radicals can be harmful to tissues, so a newer system has been
devised and tested to avert these issues. New work focuses on the creation of electrospun
dendrimer-PEG nanofiber mats (DNF) with the incorporation of poly(ethylene oxide) in a single
drug formulation of brimonidine tartrate. Compatibility and efficacy of the DNFs were studied in
rats over a three week period. It was found that DNFs and eye drop formulations had similar
responses after single doses; however, DNF formulations showed increased efficacy attributed to
accumulation of dendrimers in the anterior chamber of the eye over the three week trial(86, 87).
In related work on dendrimer hydrogels in our lab, a new approach to hydrogel synthesis
utilizes biorthogonal chemistry. This work uses copper-free click chemistry for the crosslinking
of DH as an alternative approach to potentially disruptive photoinitiators. Click chemistry uses
the high reactivity of alkynes towards azides for efficient coupling of synthetic molecules. Using
this click chemistry approach, dendrimers were loosely entangled in a physical network for the
sustained delivery of drug molecules. This approach offers catalyst-free chemistry and is highly
customizable for use in a variety of applications(87).

5.2 Cell-surface modified macrophages
In this work, distribution of nanoparticles on RAW264.6 cell surfaces was observed by
fluorescence microscopy and was found to be dependent on the stability of the linkages tethering
nanoparticles to the cell surface. The current work explored the proof-of-concept for a novel
approach to loading anti-cancer drugs onto immune cells via PAMAM dendrimers. Future work
includes optimization of the hybridization conditions, synthesis of anti-cancer drug-loaded
dendrimers, quantification of macrophage-dendrimer drug-loading capacity, and studying the
infiltration of hybridized-macrophages into tumor models. The results from this study, indicate
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that a hybridized cellular delivery system is feasible and could potentially improve drugtargeting in a range of applications.
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